Mabion Biologics at BIO International Convention 2026
- Mabion team participated in the BIO International Convention 2026 to strengthen relationships with business partners.
- During the convention, Mabion participated in two company presentations focused on strategic partnerships and next generation biologics development.
Celebration of Strategic Growth
Mabion participated in the BIO International Convention 2026. The event is one of the world’s leading biotechnology industry conventions. It brings together global biotech, pharmaceutical, investment, and partnering communities. This year’s trade fairs provided our team with an excellent platform to hold numerous high-value business meetings. It also helped the company strengthen relationships with current and potential partners.
In addition, the event enabled Mabion to establish new business contacts across the international biopharma ecosystem.
We would like to thank all partners, companies, and industry representatives who met with its team during BIO International Convention. The company looks forward to continuing the discussions initiated in San Diego and exploring new opportunities for cooperation. For follow-up discussions, please contact Mabion’s Business Development team at bd@mabion.eu.
Advancing the Business of Biologics on the BIO International Convention 2026 Stage
During the event, Mabion also participated in two company presentations on the BIO stage:
- Mabion × WPD Pharmaceuticals: From Complexity to Control: Building a Co-Development Pathway for Multivalent ADC/PDC Therapeutics (Company Presentation Theater 1, 10:30-10:45 AM).
- Mabion × ODDIFACT: 2T Therapeutics Partnership (Company Presentation Theater 3, 12:00-12:15 PM).
Unlocking Value
The cooperation between Mabion and Oddifact SAS focuses on repurposing MabionCD20. This partnership aims to reintroduce the asset as an innovative drug on rare disease indications. The project leverages Mabion’s deep biologics expertiseand Oddifact’s platform to identify new orphan drug applications.
MabionCD20 remains a project with significant scientific and commercial potential. The successful completion of the first phase and consultations with the FDA will form the basis for discussions on the next stage of collaboration, involving the further development of the project in a selected indication.
Strategic Stability
Mabion also used the BIO International Convention to highlight the extension of our long-standing cooperation with Novavax. The announcement emphasized the continued importance of this partnership for Mabion. The extension was formalized through an annex to the current agreement. Under the annex, the partnership will continue until 2029. This reinforces Mabion’s role as a trusted development and drug substance manufacturing partner for global biopharma companies.
The extension of our partnership until 2029 is a testament to the trust Novavax has placed in Mabion for many years. It also demonstrates that our expertise in biological process development, analytics and GMP-compliant manufacturing meets the highest standards of our global biopharmaceutical partners. This long-term partnership with Novavax aligns perfectly with our Strategy of building Mabion’s strong position as a flexible and technologically advanced provider of development and manufacturing services for the global biologicals market.
Prepared by:
Marketing Specialist